Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases [3] Group 1: Company Overview - Aligos Therapeutics aims to improve patient outcomes through best-in-class therapies targeting high unmet medical needs such as chronic hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH) [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1] Group 2: Presentation Details - A webcast of the presentation will be available on Aligos' website, with a replay accessible for at least 30 days following the event [2]